Global Insights: Hereditary Angioedema Therapeutics Market Expected to Surpass $15.84 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Hereditary Angioedema Therapeutics Sector?
The market size for hereditary angioedema therapeutics has seen a swift expansion in the most recent years. The projected growth will take it from $6.68 billion in 2024 to $7.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.3%. Factors contributing to the growth observed in the historical period include enhanced diagnosis and awareness, increased access to treatment, research and development efforts, educating and advocating for patients, as well as regulatory approvals.
The market for therapeutics for hereditary angioedema is projected to experience swift expansion in the coming years, reaching an estimated “$15.84 billion by 2029, translating to a compound annual growth rate (CAGR) of 19.5%.” The anticipated market growth during the forecast period could be due to progress in targeted treatments, global market enlargement, advancements in gene therapy, personalized medicine tendencies, and partnerships in therapeutic research. Dominant trends expected during this forecast include initiatives for global accessibility, research into health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What Forces Are Driving The Growth Of The Hereditary Angioedema Therapeutics Market?
The growth of the hereditary angioedema market is projected to be catalyzed by the increasing occurrence of the said disorder. Hereditary angioedema (HAE) is an uncommon genetic condition marked by recurrent incidents of severe swelling in the skin and mucous membranes. This swelling, brought about by the accumulation of excessive fluid or edema, can emerge in various parts of the body – hands, feet, face, intestines, and even airways. For example, Rare Disease Advisor, a global health care professional resource provider, revealed in June 2022 that there is 1 HAE patient for every 50,000 individuals universally, with the number of potential cases fluctuating from 1:10,000 to 1:150,000. Each year in the US, HAE episodes lead to between 15,000 to 30,000 visits to the emergency room. The time taken for diagnosing HAE differs, with 5.8% of cases taking anywhere from 0 to 6 months for a diagnosis, and another 5.8% taking over 10 years. Hence, it’s evident that the escalating prevalence of HAE is fueling the upsurge in the hereditary angioedema market.
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
How Are Key Trends Driving Expansion In The Hereditary Angioedema Therapeutics Industry?
A significant trend emerging in the hereditary angioedema therapeutics market is the emphasis on product innovation. Key players in the market are focusing on the development of novel products such as Ligand-Conjugated (LICA) experimental antisense medicine and gene therapy to maintain their market position. For example, Intellia Therapeutics, a US-based biotechnology firm in its clinical stages, introduced an Investigational New Drug (IND) NTLA-2002, in March 2023. The drug, approved by the United States Food and Drug Administration, treats hereditary angioedema and facilitates the inclusion of the US in the global phase 2 trial portion of the ongoing Phase 1/2 trial. The therapy, after a single dose, inactivates the kallikrein B1 (KLKB1) gene target permanently, thereby reducing plasma kallikrein protein activity and preventing HAE attacks. Hence, NTLA-2002 is a potential candidate for in vivo genome editing.
Which Companies Currently Dominate The Competitive Landscape In The Hereditary Angioedema Therapeutics Industry?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Which Geographic Regions Are Driving Demand In The Hereditary Angioedema Therapeutics Market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
